Vutrisiran对转甲状腺素蛋白淀粉样变心肌病心功能与结局的影响
HELIOS-B试验纳入655例ATTR-CM患者,随机接受vutrisiran 25mg每12周皮下注射或安慰剂。超声心动图显示双心室收缩与舒张功能是主要复合结局的独立预后因素,vutrisiran在18个月内减轻左、右心室收缩功能下降并改善舒张功能,这些心功能获益可能部分解释其临床结局改善。
要点
- 基线左室射血分数、整体纵向应变、三尖瓣环收缩期位移及E/e'均与主要结局独立相关。
- vutrisiran在18个月时减轻左室射血分数、整体纵向应变和三尖瓣环收缩期位移的下降。
- 18个月时这些心功能指标恶化与主要结局风险升高相关。
核心结论
- 超声心动图双心室收缩与舒张功能指标在ATTR-CM患者中提供超越NAC分期的预后信息。
- vutrisiran改善舒张功能并减轻18个月内左、右心室收缩功能下降,其心功能获益可能部分解释临床结局改善。
研究设计与样本
- HELIOS-B随机对照试验,655例ATTR-CM患者随机接受vutrisiran 25mg每12周皮下注射或安慰剂。
- 基线和第12、18、24、30个月行超声心动图,采用改良Andersen-Gill模型分析基线参数与主要结局的关联。
主要发现
- 基线左室射血分数每增加5%,主要结局HR为0.90(95%CI 0.86-0.95)。
- 基线整体纵向应变绝对值每增加1%,主要结局HR为0.92(95%CI 0.89-0.96)。
- 基线三尖瓣环收缩期心肌速度每增加1 cm/s,主要结局HR为0.94(95%CI 0.90-0.98)。
- 基线平均E/e'每增加1单位,主要结局HR为1.03(95%CI 1.01-1.04)。
- 18个月时vutrisiran组左室射血分数最小二乘均值差异为1.6%(95%CI 0.1-3.2),整体纵向应变绝对值差异为0.7%(95%CI 0.3-1.2),三尖瓣环收缩期心肌速度差异为0.5 cm/s(95%CI 0.1-0.9)。
临床怎么用
- 在ATTR-CM风险分层中,除NAC分期外应结合超声心动图双心室收缩与舒张功能指标。
- vutrisiran治疗可考虑用于延缓ATTR-CM患者心功能恶化,心功能指标变化可辅助监测治疗反应。
局限性
- 超声心动图分析仅纳入654例有可用数据的患者。
- 心功能与结局的关联分析为事后分析,不能确立因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Transthyretin amyloid cardiomyopathy (ATTR-CM), caused by deposition of transthyretin amyloid fibrils in the heart, is associated with high morbidity and mortality. In HELIOS-B (A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy), the RNA interference therapeutic agent vutrisiran reduced rates of the primary composite outcome of all-cause death and recurrent cardiovascular events among patients with ATTR-CM and had beneficial effects on cardiac structure and function over 30 months. OBJECTIVES: The purpose of this study was to investigate associations of echocardiographic measures of cardiac structure and function with the primary outcome and to assess whether favorable changes in cardiac structure and function with vutrisiran were associated with improvements in outcomes. METHODS: HELIOS-B randomized 655 patients with ATTR-CM to vutrisiran (25 mg subcutaneously every 12 weeks) or placebo. Echocardiograms were performed at baseline and months 12, 18, 24, and 30. Associations of baseline echocardiographic parameters with the primary outcome were analyzed using modified Andersen-Gill models adjusted for age, sex, ATTR disease type, and National Amyloidosis Centre stage, and stratified by baseline tafamidis use and treatment assignment. Changes in cardiac function from baseline to month 18 were compared between treatment arms and related to outcomes in landmark analyses. RESULTS: Among the 654 participants with available echocardiographic data (median age 77 years, 93% male, 88% wild-type transthyretin), baseline left and right ventricular systolic and diastolic function were independently associated with the primary outcome (HR per unit increase, left ventricular ejection fraction, 0.90 per 5% increase, 95% CI: 0.86-0.95; absolute global longitudinal strain, 0.92 per 1% increase, 95% CI: 0.89-0.96; tricuspid annular systolic myocardial velocity, 0.94 per 1-cm/s increase, 95% CI: 0.90-0.98; average E/e', 1.03 per 1-U increase, 95% CI: 1.01-1.04). At 18 months, vutrisiran attenuated declines in left ventricular and right ventricular systolic function (least squares mean difference: left ventricular ejection fraction, 1.6%, 95% CI: 0.1-3.2; absolute global longitudinal strain, 0.7%, 95% CI: 0.3-1.2; tricuspid annular systolic myocardial velocity, 0.5 cm/s, 95% CI: 0.1-0.9). Worsening in these parameters at 18 months was associated with a heightened risk of the primary outcome. CONCLUSIONS: Echocardiographic measures of biventricular systolic and diastolic function provide important prognostic information beyond National Amyloidosis Centre stage in patients with ATTR-CM. Vutrisiran improved diastolic function and attenuated declines in left ventricular and right ventricular systolic function over 18 months. The benefits on cardiac function with vutrisiran may partly underlie its beneficial effects on clinical outcomes.
引用
- Jering KS, Fontana M, Skali H, et al. Effects of Vutrisiran on Cardiac Function and Outcomes in Patients With Transthyretin Amyloidosis With Cardiomyopathy. J Am Coll Cardiol. 2025. PMID: 40769673. doi:10.1016/j.jacc.2025.06.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。